In 2014, there were an estimated 251,194 men living with testis cancer in the United States. The earlier testis cancer is caught, the better chance a person has of surviving five years after being diagnosed. 67.8% are diagnosed at the local stage and the 5-year survival for localized testis cancer is 99.3%. The number of testis cancer deaths is highest among men aged 20-34. Death rates have been stable over 2005-2014 (1).
The prognosis depends on the histology, extent of the disease, localization of metastases, tumor size and level of tumor markers. Patients with extragonadal nonseminoma with mediastinal localization fall into a poor prognostic group. Relapse after previous chemotherapy generally has a poor prognosis. About 25% of the patients live for 5 years. (2)
Five percent of patients with testicular cancer will develop new cancer in the contralateral testicle in their lifetime. (4)
All patients with metastasizing seminoma have either a good or intermediate prognosis. Seminoma in the good prognosis group has a 5-year survival of 86%, while the intermediary prognosis group has a 72% survival. (7)
Nonseminoma in the good prognostic group has a 5-year survival of 92%. In the intermediary prognostic group, 5-year survival is 80%. The poor prognostic group has a 48% of 5-year survival. (8)
Five-year relative survival of patients with testicular cancer, in percent, according to stage during the diagnosis period 1974–2013.
Source: Cancer Registry of Norway